PPARGC1A and chronic obstructive pulmonary disease: Although the therapeutic effect of resveratrol in treating COPD through activating SIRT1 and PGC-1α expression have been verified in animal models, a double-blind, randomized, placebo-controlled study revealed contrasting results (Beijers et al., 2020).